Loading
Sentiment · FY2026 Q2
As of FY2026 Q1, the Tellvest earnings-call sentiment score for AbbVie (ABBV) is 9/10.
AbbVie delivered 12.4% revenue growth to $15 billion with adjusted EPS of $2.65 exceeding guidance by $0.07, driven by exceptional immunology performance as Skyrizi and Rinvoq continued their rapid adoption in IBD and other indications. Neuroscience momentum accelerated across the portfolio while the Crohn's combination platform showed transformational efficacy data. Management raised full-year EPS guidance by $0.12 to $14.08-$14.28 on the strength of the Q1 beat.
Scored from AbbVie’s FY2026 Q1 earnings call. The newest quarter is available with Tellvest Pro.
Full Pro access for 30 days when you create a free account. No credit card required.
All prior quarters are free.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $15.10B | +5.6% | $-0.02 | -103.9% | 70.9% | -9.9% | -0.1% | $6.76B |
| FY2025 Q1 | $13.34B | +8.4% | $0.72 | -6.5% | 70.0% | 28.0% | 9.6% | $1.40B |
| FY2025 Q2 | $15.42B | +6.6% | $0.53 | -31.2% | 71.8% | 31.7% | 6.1% | $4.88B |
| FY2025 Q3 | $15.78B | +9.1% | $0.10 | -88.7% | 66.4% | 12.1% | 1.2% | $7.53B |
| FY2025 Q4 | $16.62B | +10.0% | $1.02 | +5735.4% | 72.6% | 35.0% | 10.9% | $4.89B |
| FY2026 Q1 | $15.00B | +12.4% | $0.39 | -45.8% | 71.9% | 31.6% | 4.7% | $3.56B |
| FY2026 Q2 | $16.99B | +10.2% | $2.04 | +284.9% | 84.7% | 39.6% | 21.3% | — |